GO:0034482 chondroitin 2-sulfotransferase activity

Chondroitin 2-sulfotransferase activity (GO:0034482) is a molecular function that catalyzes the transfer of a sulfate group from 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to the C2 position of uronic acid residues within chondroitin and dermatan sulfate glycosaminoglycans. This modification is crucial for the structural and functional diversity of proteoglycans, which are key components of the extracellular matrix and cell surfaces. The enzyme responsible, encoded by CHST14 in humans, specifically sulfates iduronic acid and glucuronic acid residues, thereby influencing the physicochemical properties of these polysaccharides. Understanding this activity is fundamental for researchers studying connective tissue biology, developmental processes, and related disorders. The importance of chondroitin 2-sulfotransferase activity extends beyond basic glycobiology. It plays a role in modulating growth factor signaling, cell adhesion, and matrix assembly, and its dysregulation has been linked to human diseases such as adducted thumb-clubfoot syndrome. Moreover, the enzyme's substrate specificity and catalytic mechanism have been characterized through mutational and biochemical studies, providing insights into the broader family of sulfotransferases. As the field moves toward precision models, tools like CRISPR gene editing enable the creation of isogenic cell lines with defined mutations in CHST14, facilitating detailed structure-function analyses. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a comprehensive overview of GO:0034482, covering its definition, mechanism, key genes, disease associations, and research methodologies. By integrating these aspects, we aim to support both fundamental research and the development of therapeutic strategies targeting glycosaminoglycan sulfation.

Chondroitin 2-sulfotransferase activity is defined as the catalysis of the reaction: 3'-phosphoadenosine 5'-phosphosulfate (PAPS) + chondroitin = adenosine 3',5'-bisphosphate + chondroitin 2'-O-sulfate. This enzymatic activity results in the sulfation of glucuronic acid and iduronic acid residues within chondroitin and dermatan sulfate chains, thereby modifying the glycosaminoglycan structure.

Chondroitin 2-sulfotransferase activity is essential for the proper biosynthesis of dermatan sulfate and chondroitin sulfate, which are critical components of the extracellular matrix and play roles in cell signaling, adhesion, and tissue morphogenesis. The enzyme's ability to sulfate iduronic acid residues is particularly important for the unique properties of dermatan sulfate, and its dysfunction leads to connective tissue disorders such as adducted thumb-clubfoot syndrome. Furthermore, understanding this activity provides a basis for developing therapeutic interventions targeting glycosaminoglycan metabolism in cancer, fibrosis, and developmental diseases.

The following genes and proteins are directly involved in chondroitin 2-sulfotransferase activity or its regulation, as supported by published literature.

The activity of chondroitin 2-sulfotransferase is regulated primarily at the level of enzyme expression and substrate availability. The enzyme's mRNA levels can be modulated by growth factors and cytokines, although specific transcriptional regulators have not been fully elucidated. Post-translational modifications, such as phosphorylation, may affect enzyme activity, but direct evidence is limited. The availability of the sulfate donor PAPS, which is synthesized by PAPS synthases (PAPSS1 and PAPSS2), is a critical determinant of sulfation capacity. Additionally, the composition of the glycosaminoglycan chain, particularly the presence of iduronic acid generated by dermatan sulfate epimerases (DSE and DSEL), influences the enzyme's activity. Feedback inhibition by the reaction product PAP may also play a role in regulating flux through the sulfation pathway.

Mutations in CHST14, the gene encoding chondroitin 2-sulfotransferase, cause adducted thumb-clubfoot syndrome (ATCS), a rare autosomal recessive connective tissue disorder characterized by congenital contractures, distinct facial features, and skeletal abnormalities. Loss of enzyme activity leads to reduced dermatan sulfate sulfation, affecting collagen fibrillogenesis and extracellular matrix integrity. This condition highlights the critical role of chondroitin 2-sulfotransferase in human development and tissue homeostasis.

Altered expression of chondroitin sulfate sulfotransferases, including CHST14, has been observed in various cancers. Changes in glycosaminoglycan sulfation patterns can affect tumor cell adhesion, migration, and invasion, as well as interactions with growth factors and chemokines. Although direct mutations in CHST14 are not common in cancer, dysregulated sulfation pathways may contribute to malignant phenotypes, making this enzyme a potential target for therapeutic intervention.

Beyond ATCS, defects in dermatan sulfate biosynthesis can lead to a spectrum of connective tissue disorders, including Ehlers-Danlos syndrome-like phenotypes. Fibrotic conditions are associated with altered glycosaminoglycan deposition, and chondroitin 2-sulfotransferase activity may influence the progression of fibrosis by modulating matrix stiffness and growth factor signaling. Understanding these mechanisms could inform the development of antifibrotic therapies.

Direct measurement of chondroitin 2-sulfotransferase activity is typically performed using radioactive or fluorescently labeled substrates. The enzyme is incubated with PAPS (often radiolabeled with 35S) and chondroitin or dermatan sulfate, and the incorporation of sulfate into the glycosaminoglycan is quantified. These assays are essential for determining kinetic parameters, substrate specificity, and the effects of mutations.

Mass spectrometry, often coupled with liquid chromatography (LC-MS), is used to determine the sulfation patterns of chondroitin and dermatan sulfate chains. After enzymatic digestion, the disaccharides are analyzed to quantify the proportion of 2-O-sulfated uronic acid residues. This method provides a comprehensive view of how CHST14 activity affects the overall glycosaminoglycan composition.

CRISPR-Cas9 is employed to generate knockout, point mutation, or knock-in cell models to study the function of CHST14 and related genes. Knockout cells lacking CHST14 exhibit reduced 2-O-sulfation and altered dermatan sulfate structure, providing a platform to test rescue constructs or investigate downstream effects. Point mutations can be introduced to mimic patient alleles, allowing structure-function studies.

Specific antibodies against chondroitin 2-O-sulfate (e.g., 2B6 or MO-225) can be used in immunofluorescence or immunohistochemistry to localize the modified glycosaminoglycans in tissues and cells. Tagged versions of CHST14 (e.g., GFP fusion) enable live-cell imaging to study its subcellular localization and trafficking.

Researchers studying chondroitin 2-sulfotransferase activity-related genes often need to determine whether a candidate gene is causally involved in glycosaminoglycan sulfation, matrix assembly, or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation and accelerating discovery in glycobiology and related fields.

Chondroitin 2-sulfotransferase activity (GO:0034482) is a key enzymatic function in glycosaminoglycan biosynthesis, responsible for the 2-O-sulfation of uronic acid residues in chondroitin and dermatan sulfate. Its importance is underscored by its role in connective tissue disorders such as adducted thumb-clubfoot syndrome and its potential involvement in cancer and fibrosis. Advances in CRISPR-based models and analytical techniques continue to unravel the mechanistic details and disease relevance of this activity, offering opportunities for therapeutic intervention. EDITGENE's suite of CRISPR services supports researchers in generating precise cell models to study CHST14 and related genes, facilitating discoveries in glycobiology and beyond.